ArticleAntioxidants (Basel, Switzerland)2026
Sphingolipid Remodeling and Extracellular Vesicle Signatures Reflect Disease Severity in Facioscapulohumeral Dystrophy Driven by Mitochondrial Dysfunction and Endoplasmic Reticulum Stress.
Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundFacioscapulohumeral muscular dystrophy (FSHD) is a progressive and heterogeneous disorder lacking reliable circulating biomarkers for disease monitoring and therapeutic response. We hypothesized that metabolic dysregulation, lipotoxicity, and endoplasmic reticulum (ER) stress induce sphingolipid remodeling that is reflected in serum and correlates with disease severity.
methodsWe performed RNA sequencing, differential expression, and pathway analyses on biceps brachii muscle biopsies from mild (
resultsSevere FSHD exhibited transcriptomic signatures of mitochondrial dysfunction, ER stress, inflammation, and extracellular vesicle biogenesis. RNA-seq revealed activation of the de novo ceramide synthesis pathway, with increased SPTLC1-3, CERS2, CERS5, and DEGS1, reduced SMPD1/4 and SMPDL3A, and dysregulation of cerebroside metabolism. Migrasome/extracellular vesicle markers (TSPAN4, TM4SF1, PIGK, CPQ, ITGA5, and ITGB1) were predominantly upregulated in patients with severe disease. Serum lipidomics showed severity-dependent increases in dihydroceramides, ceramides, sphingomyelins, and dihydrosphingomyelins, while the Cer/HexCer d18:1/18:0 ratio progressively increased with disease severity.
conclusionsIntegrated transcriptomic and lipidomic analyses identify sphingolipid dysregulation and extracellular vesicle biogenesis as hallmarks of severe FSHD and support circulating sphingolipids as candidate biomarkers for disease severity and therapeutic monitoring.
Indexed as
Identifiers
42792205What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.